Key facts
- Notable investors include Miraidoa.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Physios Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Physios Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Physios Biotech
Developer of microphysiological systems intended to return technology in the MPS field to society. The company develops MPS with high extrapolation to humans and MPS that reproduce rare diseases, and contributes to reducing animal testing, shortening drug development time, and safety evaluation of compounds and also works on enabling scientists to evaluate new therapeutic drugs for rare cancers, reproducing the cancer microenvironment, and co-culturing with three-dimensional tissues.
- Sector
- Healthcare
- HQ
- Morioka City, Japan
- Founded
- 2023
- Website
- physiosbiotech.com/
- Ownership
- Privately Held (backing)
Physios Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Physios Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Physios Biotech in its N-PORT filings yet. We sweep new filings monthly.